恩典生命科技 02112.HK 深 沪
交易中 12-16 11:24:14
0.059
+0.002
+3.51%
华盛通- 最 高0.066
- 今 开0.054
- 成交量 4000股
- 最 低 0.054
- 昨 收 0.057
- 总市值 8850.00万
- 52周最高 0.187
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.044
- 委 比 6.28%
- 总股本 15.00亿
- 历史最高 0.065
- 量 比 0.10
- 振 幅 21.05%
- 历史最低 0.044
- 每 手 2000
- 风险率 0.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多恩典生命科技（02112.HK）11月25日收盘平盘
证券之星消息，截至2025年11月25日收盘，恩典生命科技(02112.HK)报收于0.06港元，与上一交易日持平，成交量4.0万股，成交额2416.0港元。
11-25 19:06
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Grace Therapeutics获得美国专利号12,414,943，涉及尼莫地平的静脉给药方案，专利有效期至2043年。该专利加强了GTx-104的知识产权保护，结合其孤儿药指定带来的7年市场独占权，进一步巩固了其市场地位。STRIVE-ON试验显示，GTx-104在安全性及疗效方面优于口服尼莫地平，为公司未来商业价值及股东回报提供有力支持。
09-18 12:30
恩典生命科技(02112.HK)发布中期业绩，股东应占溢利21.1万美元
恩典生命科技(02112.HK)发布2025年中期业绩，收入841.7万美元，同比增长41%;母公司拥有人应占溢利21.1万美元，上年同期亏损896.6万美元;每股基本盈利0.01美仙。
08-29 22:30
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Grace Therapeutics submitted its New Drug Application (NDA) to the FDA for GTx-104, an injectable nimodipine formulation for treating aneurysmal subarachnoid hemorrhage (aSAH). The application includes positive results from the Phase 3 STRIVE-ON safety trial, which showed GTx-104 met its primary endpoint with a 19% reduction in clinically significant hypotension compared to oral nimodipine. The submission could trigger up to $7.6 million in warra...
06-25 12:00
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
Grace Therapeutics held a Type C meeting with the FDA regarding their planned NDA submission for GTx-104, which is on track for submission by mid-2025. The company reported successful completion of the STRIVE-ON trial, meeting its primary endpoint and showing potential clinical benefits compared to oral nimodipine. They secured $15 million in private placement financing, with potential for an additional $15 million, strengthening their cash posit...
06-23 12:00
